diaDexus Inc reports launch of clinical programme to support the submission of its PLAC Test for Lp-PLA2 Activity.
M2 PHARMA-October 16, 2013-diaDexus Inc reports launch of clinical programme to support the submission of its PLAC Test for Lp-PLA2 Activity(C)2013 M2 COMMUNICATIONS
Cardiovascular company diaDexus Inc (OTC Markets:DDXS) reported on Tuesday that it has started a clinical programme to support the submission of its PLAC Test for Lp-PLA2 Activity.
This important next step in the regulatory clearance process follows the company's recent pre-submission meeting with the US Food and Drug Administration (FDA).
According to the company, it has partnered with a large longitudinal cardiovascular disease study to validate the PLAC Test for Lp-PLA2 Activity.
The company expects the clinical study sample analysis prior to the end of the first quarter of 2014.
In addition, the company said its PLAC Tests are simple blood tests that uncover the hidden risk of heart attack by measuring Lp-PLA2, a vascular-specific inflammatory marker critical in the formation of rupture-prone plaque. Lp-PLA2 levels aid in cardiovascular disease risk assessment independent from other biomarkers - providing distinct insight into the relationship among inflammation, atherosclerosis and cardiovascular outcomes.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Date:||Oct 16, 2013|
|Previous Article:||Mersana Therapeutics Inc awarded first preclinical milestone payment from Endo Pharmaceuticals.|
|Next Article:||Life Technologies Corporation extends partnership with DNAVEC Corporation for CytoTune-iPS 2.0 Sendai Reprogramming Kit for Sendai virus-based tools.|